Inflammatory Bowel Disease and Thrombosis

İnflamatuvar Bağırsak Hastalığı ve Tromboz

Ahmet Tezel¹, Muzaffer Demir²

¹Trakya University, School of Medicine, Department of Gastroenterology, Edirne, Turkey
²Trakya University, School of Medicine, Department of Hematology, Edirne, Turkey

Abstract

Inflammatory Bowel Disease (IBD) is a group of chronic and relapsing inflammatory disorders of the gastrointestinal system. In these cases, findings are detected in extraintestinal systems also. There is a tendency for thrombotic events in IBD, as in the other inflammatory processes. The pathogenesis of this thrombotic tendency is multidimensional, including lack of natural anticoagulants, prothrombotic media induced via the inflammatory process, long-term sedentary lifestyle, steroid use, surgery, and catheter placement. The aim of this review was to highlight the positive relationship between IBD and thrombotic events, and the proper treatment of at-risk patients.

Key Words: Inflammatory bowel disease, Thrombosis

Introduction

Inflammatory bowel disease (IBD) is a group of disorders characterized by chronic, relapsing inflammation of the gastrointestinal system triggered by environmental factors in genetically susceptible individuals. The primary diseases that constitute IBD are ulcerative colitis (UC) and Crohn’s disease (CD). Systemic findings related to and not related to inflammatory activity may be observed in addition to gastrointestinal findings in both diseases. The etiopathogenesis of IBD is not been fully known. The genetics of IBD remain the greatest mystery. Clinical findings vary according to periods of inflammatory activity and remission. Drugs used for treatment cause additional clinical findings and morbidity.

The strong relationship between inflammation and hemostasis affects the progression and severity of disease in many inflammatory pathologies, including IBD, atherosclerosis, and rheumatoid arthritis [1]. The tendency for thrombosis in IBD has been known since 1936. Bargen and Barker [2] reported that life-threatening thromboemb...
bolic events develop in UC cases and that the tendency for thrombosis might be associated with thrombocyte dysfunction or increased thromboplastin synthesis. Thereafter, other case reports and prospective studies reported the potential for thrombosis to develop in venous and arterial systems [3-7].

The present review aimed to evaluate the relationship between IBD and thrombosis. Inconsistent results, variation in study design, and insufficient clarification of the development of thrombosis in IBD complicate the issue.

Answering following questions may help understanding the relationship between IBD and thrombosis better.

1. Is there a real tendency to thrombosis in IBD? What is the magnitude of the problem?
2. With which mechanism does thrombosis develop in IBD?
3. Is there a relationship between thrombosis development and disease activity?
4. Can thrombotic pathologies be prevented?
5. Can anticoagulant agents be used in treatment of the disease?

**Thrombosis tendency in IBD**

Thrombosis tendency is accepted to increase in IBD. Thrombosis is encountered in arterial and more commonly in venous system besides microvascular mucosal thrombosis. Thrombosis arises in deep crural veins, pulmonary circulation, less commonly in cerebrovascular system, portal vein and retinal veins [3-7]. When we analyzed the magnitude of the problem; frequency of systemic thromboembolism in IBD varies between 1-7% and reaches to 39% in some autopsy series [3,8,9]. In the study of Bernstein et al. [10] deep venous thrombosis and pulmonary embolism are three fold higher among IBD cases compared to normal population. In addition to this, detection of the fact that IBD was less frequent among patients who have hemophilia and von Willebrand disease [11,12]. This prothrombic condition was suggested to be able to play a role in pathogenesis of especially CD; multifocal microscopic ulcerations were detected even in healthy mucosa biopsies macroscopically [13].

Many factors that may lead to thrombosis are available in inflammatory bowel diseases and these factors are summarized in Table 1 [14].

**Table 1:** Hereditary and acquired prothrombic risk factors in IBD [14].

| Hereditary risk factors |
|-------------------------|
| Factor V Leiden mutation |
| Prothrombin G20210A gene mutation |

| Acquired risk factors |
|-----------------------|
| Inflammation and acute medical conditions |
| Longstanding immobility |
| Surgical interventions |
| Steroid treatment |
| Central venous catheter insertion |
| Hyperhomocysteinemia |
| Anti-phospholipid antibodies |
| Others |

gene mutation, C677T methylenetetrahydrofolate reductase gene mutation, Factor XIII gene mutation and plasminogen activator inhibitor type I gene polymorphisms were held to account in IBD and thrombophilia relationship [15]. *Factor V Leiden mutation* is a member of protein C natural anticoagulant system and is activated by binding thrombin to thrombomodulin on the endothelial surface (APC). APC inhibits uncontrolled thrombosis formation by inactivating factor V and VIII. Arg506 Gln point mutation on factor V gene (factor V Leiden) makes factor V resistant against inactivation by APC [14,16]. While frequency of factor V Leiden (FVL) is 2%-5% among Europeans, it was not found in native Africans, Native Americans and in Asia [17-20]. Its frequency was found as 7.9% as the results of studies carried out with healthy populations over the country [21]. FVL is the most common cause of thrombophilia and accounts for approximately 11-20% of acute venous thrombotic events [17].

IBD-FVL relationship was studied widely due to high frequency of FVL and because IBD is a prothrombotic condition. In a meta-analysis, a significant difference was not found between IBD cases and normal subjects in terms of FVL frequency [14]. However distinct results were reported in two studies. While FVL was found more frequent among CD cases compared to UC cases and healthy controls in the first one, FVL was found more frequent among UC cases compared to CD cases and healthy controls in the study of Halsam et al. [22]. These different results were tried to be explained with low number of patients and difference in geographic distribution of the mutation in meta-analysis of Papa et al. [14].
When thrombotic and non-thrombotic IBD cases were compared; Liebman et al. [19] found FVL in 36% of cases with thrombosis in their retrospective study. In the same study, they calculated IBD and FVL coincidence 23 fold greater compared to healthy subjects, risk of venous thrombosis development risk as 5-fold greater than non-thrombotic IBD cases. They suggested that FVL mutations had significant contribution on venous thrombosis development in IBD cases. The fact that venous thromboembolism risk increased in presence of FVL and especially before 45 years of age was confirmed in another study [23].

In a study reported from Turkey this year, it was stated that protein S and antithrombin III levels decreased along with protein C in active periods of both UC and CD; however no difference was reported in remission period. Additionally, activated protein C resistance was found indifferent from control group in active period and remission period. In this study, natural anticoagulant deficiency was emphasized to be able to lead to thrombophilia especially in cases in active period [24].

**Prothrombin G20210A gene mutation**

Prothrombin (PT) is a protein synthesized from the liver with the effect of vitamin K and converted to thrombin by prothrombinase complex in the course of coagulation. PT gene mutation develops by guanine adenine exchange at the 20210 position. PT level was found approximately 30% more in heterozygous subjects compared to healthy controls [14]. However a correlation was not found between IBD cases and PT gene mutation [9,25].

**C677T methylenetetrahydrofolate reductase gene mutation and hyperhomocysteinemia**

Hyperhomocysteinemia is a risk factor for both arterial and venous thromboembolism. Hyperhomocysteinemia may arise as the result of a genetic defect (C677T methylenetetrahydrofolate reductase gene mutation) and also as the result of deficiency of cofactors like vitamin B12, B6 and folate [26]. Endothelial damage is in question following endothelial dysfunction and thrombocyte activation in development of hyperhomocysteinemia-related thrombosis. Homocysteine converts to homocysteine, homocysteine thiolactone and mixed disulfides via rapid auto-oxidation in plasma, strong reactives like superoxide and hydrogen peroxide and this is more prominent especially in cases with hyperhomocysteinemia.

Homocysteine thiolactone and LDL conjugate and form aggregates, this leads to foam cell formation and contributes to reactive oxygen radical development. Reactive oxygen radicals lead to endothelial damage and dysfunction, this leads to excessive platelet activation and aggregation. Thrombosis in hyperhomocysteinemia was detected to be rich of platelets. Reactive oxygen radicals also contribute to thrombosis development by oxidizing LDL, leading to lipid peroxidation and causing proliferation in vascular smooth muscle cells [26].

Relationship between hyperhomocysteinemia and thrombosis development in IBD was researched widely. Hyperhomocysteinemia may be genetic in origin and also develops related to deficiency of cofactors like B6, folate and B12 vitamins that are effective on homocysteine metabolism. Nutritional insufficiency, impairment in absorption and decrease in their levels due to effects of drugs like sulfasalazine may be seen in IBD [27,28]. In two studies investigating IBD and hyperhomocysteinemia coexistence, homocysteine levels were found to be significantly higher in IBD cases compared to healthy subjects however a relationship could not be found between hyperhomocysteinemia and thrombosis development in both studies [29,30].

On the other hand, C677T methylenetetrahydrofolate reductase gene mutation was also investigated as the cause of hyperhomocysteinemia in IBD and conflicting results were reported. While C677T mutation was found significantly higher in IBD cases compared to healthy individuals in two studies held in Northern Europe [9,31], there are studies reporting C677T mutation frequency in IBD as high as healthy individuals [28,32,33].

When evaluating C677T homozygosity and disease relationship, it should be kept in mind that this mutation may differ significantly according to ethnic and geographic factors. For example, while it is never seen in Africans, it was found highest among Italians and Spanish people [18-20%], moderate in northern countries like Germany, Holland, Norway, Ireland 87-10%) [34]. Thus it is obvious that C677T mutation in healthy individuals and subjects with IBD would give different results in the studies held in aforementioned countries or groups.

In general, absence of a correlation between FVL, prothrombin gene mutation, C677T methylenetetrahydrofolate reductase gene mutations and IBD is not surprising. Although complex genetics of IBD has not been fully explained, association of genomic regions on chromosomes 12 and 16 with diseases was shown [35]. On the other hand, prothrombic mutations were shown to be on genes located on chromosomes 1 and 11 in the study of
Vecchi et al. [32]. As the result, congenital thrombophilic disorders and IBD do not take place on the same genetic basis.

**IBD and Hemostasis Relationship**

Many factors related to the nature of the disease, metabolic outcomes and drugs might lead to different conditions in the course of IBD; they also may contribute to thrombosis formation [36].

**Inflammation and inflammatory activity**

Chronic intestinal inflammation triggered by luminal antigens in genetically susceptible subjects may be stated as the environmental factor in IBD. We can consider different wall structures of gram negative and anaerobic bacteria, bacteria products and dietary antigens as luminal antigens. Developing immunologic events, tissue damage and repair develop in a similar manner independently from the initiating factor in intestinal inflammation. Immune, mesenchymal and epithelial cells activated in intestinal wall implement tissue damage and repair via some soluble mediators. These mediators include cytokines, arachidonic acid metabolites and growth factors. While intestinal inflammation may be controlled in healthy individuals, down regulation of inflammation is not probable in IBD cases. If antigenic stimulus continues, inflammatory response arises gradually getting strong. This property (misfortune) is responsible for chronicity and disease in IBD cases.

Many soluble mediators play an important role in pathogenesis of the disease in IBD. These may include arachidonic acid metabolites (prostaglandin E2 [PGE2], thromboxane A2 [TXA2], and leukotriene B4 [LTB4]), platelet activating factor (PAF), cytokines (IL-1, IL-2, TNF-a, IL-8, IFN-g), and intercellular adhesion molecules (ICAM-1, etc.). On the other hand, cytokines like IL-4, IL-10 and IL-13 play roles in stabilization of inflammation, growth factors like transforming growth factor - beta (TGF-b) play roles in tissue repair [36]. PAF is synthesized and released by monocytes, neutrophils, basophils, mast cells, vascular endothelial cells and epithelial cells during inflammation [36]. Biologic effects of PAF are stimulation of thrombocyte and neutrophil aggregation, chemotaxis, stimulation of eicosanoid and IL-8 synthesis, contraction of smooth muscle cells and increasing mucosal chloride secretion. In active IBD cases, increased PAF was found in ileal and colonic mucosa biopsies and in feces [37]. Chiaramntini et al. [12] detected an increase in aggregation of platelets. Although statistically insignificant, hyperaggregability was reported significantly in CD and no relationship was found between disease activity. Authors suggest that this may be related to PAF rather than TXA2 [11].

Systemic inflammation is accepted as a strong prothrombic stimulus. While inflammatory events increase procoagulant factors, they decrease natural anticoagulants and fibrinolytic activity [38]. Effects of inflammation on coagulation are summarized in Table 2.

Hemostatic changes in the course of IBD are related to activity and severity of the disease. Alterations in hemostasis were widely investigated in experimental and clinical studies. One of the mainly affected compounds is platelets and changes both in activities and numbers of the platelets are detected.

Kapsoritakis et al. [39] researched thrombopoietin (TPO) level that is a physiologic regulator of thrombopoiesis in IBD. While platelet count increases in active cases and this is used as an important indicator of inflammation-normalizing was detected in inactive cases, on the other hand, TPO level was found high independently from activity. A significant relationship could not be found between TPO level, and the platelet count, erythrocyte sedimentation rate, or C-reactive protein level. Authors reported that TPO could be related to procoagulant property of IBD besides platelet production [39]. Thrombocytosis and low volume platelets were proven to be associated with disease activity. Expression of activation proteins like P-selectin, GP53 and CD40-ligand increased both in UC and CD. Plasma CD40 ligand level was associated with prevalence of anatomic involvement. Presence of platelet aggregates was shown in mucosal biopsies of UC patients. Activation of platelets can be indicated with presence of platelet-leucocyte complexes in circulation [40].

**Table 2: Effects of inflammation on hemostasis [38].**

| The ones increase in inflammation |  |
|----------------------------------|--|
| Tissue factor                    |  |
| Membrane procoagulant lipid     |  |
| Platelet reactivity             |  |
| Fibrinogen                       |  |

| The ones decrease-suppressed inflammation |
|------------------------------------------|
| Thrombomodulin (TM)                     |
| Endothelial cells protein C receptor (EPCR) |
| Shortening in APC half time             |
| Protein Z                                |
| Vascular heparin-like molecules         |
| Fibrinolysis (Increase in PAI-1)         |
Various steps of coagulation-fibrinolytic system were analyzed in active and remission periods of IBD. In the studies, it was reported that measurement of coagulation factor level was not healthy enough because IL 6 and TNF alpha and hepatic synthesis of these proteins could increase as acute phase reactants [8,41]. Thus prothrombin fragment 1+2 (F1+2) was reported to give better outcomes as the indicator of coagulation activation, fibrin degradation products (FDP) were reported to give better outcomes as the indicator of fibrinolytic system [39].

F1+2 and FDP levels were found high as indicating activation of coagulation and fibrinolytic system independently from inflammatory activity in IBD [8, 12,41]. FDP were found significantly low in cases using corticosteroids. Authors reported that corticosteroid usage caused risk for thrombosis development by decreasing fibrinolytic activity [41].

Another indicator of coagulation activation in IBD patients is thrombin increase. In other words, prothrombic property of the disease was proven by endogenous thrombin formation-another indicator of coagulation activation in IBD patients. That thrombin formation increased with CRP elevation or disease activity was shown with endogenous thrombin potential by Saibeni et al. Why thrombosis formation is more in active period is explained with these data [42].

As in all inflammatory events, fibrinolytic system inhibition is seen also in IBD patients. Decrease in tissue plasminogen activator (tPA)-fibrinolytic system activator- and increase in plasminogen activator inhibitor (PAI) -fibrinolytic system inhibitor- were detected [43]. Besides, frequencies of autoantibodies against compounds of coagulation system, especially phospholipids and protein S have also increased. However clinical importance of these antibodies is controversial.

**Acquired risk factors**

Factors like longstanding immobilization, surgical intervention, corticosteroid treatment, and central venous catheter insertion considered among acquired factors are effective for thrombosis development not only in IBD but also in many other diseases. In a study carried out for detection of thrombosis risk, only corticosteroid use was found as a factor increasing thrombosis risk [9], on the other hand, in another study active illness, intestinal stenosis and fistula were reported as risk factors [23]. Age of thrombosis development was found earlier in both studies compared to non-IBD causes. Not only hospitalized patients but also patients followed up in outpatient setting in active period were shown to be risky for thromboembolism. Grainge et al. [44] investigated venous thromboembolism risk between periods of inflammatory bowel disease and found that cases in active period were more risky in pre-hospitalization period compared to the patients who were hospitalized. While this risk is prominent both in episodes and chronic active cases, it is less in cases in remission. [Hazard ratio 15.8 (9.8-25.5) during episodes in outpatient setting, 9.9 (6.7-14.7) in chronic active cases, 2.2 (1.5-3.2) in cases in remission, 3.2 (1.7-2.3) during episodes in hospitalized cases, 2.8 (1.5-5.2) in chronic active cases, 1.7(1.1-2.9) in remission, 95% CI]. Thrombosis risk was shown to increase among IBD cases in subjects with acute medical diseases [45-47]. Using data of these multi-center randomized studies, IBD was also added to risk assessment scales used for detection of thrombosis risk in patients hospitalized due to acute medical diseases [48].

**May thrombosis development be prevented in IBD?**

Although IBD is accepted as a prothrombic clinical condition, a treatment preventing thrombosis development is not available in daily practice due to the fact that thrombosis physiopathology could not be fully enlightened, IBD-specific risk factors could not be fully determined except for corticosteroid use. Patient education is of great importance as general measures. Prevention of longstanding immobilization, counteracting smoking, and careful monitoring of subjects who underwent surgical intervention and who were inserted catheters are recommended. Besides, pharmacologic and mechanical thromboprophylaxis should definitely be made (with low molecular weight heparin) if there is not a contraindication in patients older than 40 years who are hospitalized and stay immobilized longer than 3 days.

**Heparin use in IBD**

Traditional treatment modalities like corticosteroids, 5-ASA/sulphasalazine, immunosuppressive drugs lead to additional morbidities in IBD and increase number of surgical interventions. In recent years, heparin use has taken place among alternative medical treatment methods with immunomodulatory drugs.

Accepting IBD as a prothrombic condition, indicating intestinal microthrombosis even in histologically normal mucosa arises the opinion to benefit from anticoagulant effect of heparin [49]. Anticoagulant effect of heparin is inhibition of factor X in presence of antithrombin in plasma and inhibiting thrombin formation [48]. However
heparin has immunomodulatory and anti-inflammatory effects besides well-known anticoagulant effect. These effects are summarized in Table 3. [49-51]

Heparin is currently used as an alternative treatment in UC cases resistant to steroid. Three studies are available about this topic; heparin was used with an initial dose of 25,000-40,000 IV daily for 4-6 weeks, aPTT so as to be 60", 54%-90% remission was reported [52-54]. Some of the patients were administered subcutaneous heparin during 6 weeks-4 months and no relapses were reported after the drug had been discontinued. Heparin was tolerated well in these studies; the most frightening adverse reaction colonic bleeding was seen in 5% cases.

Törkvist et al. [55] used dalteparin sodium (low molecular weight heparin) 5000 U SC bid during 12 weeks in 12 active UC cases resistant to steroid. They obtained clinical improvement in 11 (92%) cases and complete remission in 6 (50%) cases and reported no adverse effects. Authors suggested that low molecular weight heparin could be a good alternative due to its safety.

On the other hand, in the prospective, randomized, double blind, placebo controlled, multicenter study of Bloom et al. [56] including 100 UC cases with mild or moderate activity, they reported that tinzaparin was not superior to placebo. In the meta-analysis of Shen et al. [57], both low molecular weight and standard heparin were reported not to be superior to conventional treatment and provided no additional benefits in ulcerative colitis cases. In addition to this, while importance of biologic agents in IBD treatment is gradually increasing in recent years, use of heparin and heparin derivatives for anti-inflammatory purpose has played second fiddle [58].

**Conclusion**

The best example for interaction between hemostasis and inflammation is IBD. According to obtained experimental and clinical data, it is accepted as a medical condition that thrombosis frequency increased. Thus the fact that thromboprophylaxis is necessary especially for subjects who are planned to be hospitalized has been proven with clinical studies. Thromboprophylaxis may be done with pharmacologic and/or mechanical methods however pharmacologic methods are known to be superior. Although the most frightening adverse effect is bleeding, frequency of bleeding has not been increased compared to placebo in cases that standard or low molecular weight heparin had been used. Besides, wound healing occurs faster due to anti-inflammatory and immunomodulatory properties of heparin molecules except for anticoagulant properties and the disease remits easily. Evaluating use of anticoagulants in IBD from this point of view would be beneficial. Heparins', especially low molecular weight heparins' introduction as an alternative treatment among future treatment modalities is probable.

**Conflict of Interest Statement**

The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.
References

1. Yoshida H, Granger DN: Inflammatory bowel disease: A Paradigm for the link between coagulation and inflammation. Inflamm Bowel Dis 2009; 15: 1245-1255

2. Bargen JA, Barker NW: Extensive arterial and venous thrombosis complicating chronic ulcerative colitis. Arch Intern Med 1936; 58: 17-31

3. Talbot RW, Heppel J, Dozois RR, Beart RW Jr: Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986; 61: 140-145

4. Johns DR: Cerebrovascular complications of inflammatory bowel disease. Am J Gastroenterol 1991; 86: 367-370

5. Keyser BJ, Hass AN: Retinal vascular disease in ulcerative colitis. J Clin Ophthalmol 1994; 118: 395-396

6. Fichera A, Cicciollo LA, Mendelson DS, Greenstein I, Heimann TM: Superior mesenteric vein thrombosis after colectomy for inflammatory bowel disease: A not uncommon cause of postoperative acute abdominal pain. Dis Colon Rectum 2003; 46: 643-648

7. Ribeiro JM, Rebocho L, Lucas MB, Campos P, Victorino RM: Brachiocephalic vein thrombosis associated with Crohn’s disease. J Gastroenterol 2004; 38: 268-271

8. van Bodegraven AA, Schoorl M, Baak JP, Linskens RK, Bartels PC, Tuyman HA: Hemostatic imbalance in active quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 487-493

9. Grip O, Svensson PJ, Lindgren S: Lindgren Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol 2000; 35: 619-623

10. Bernstein CN, Blanchard JF, Houston DS, Wajda A: The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: A population-based cohort study. Thromb Haemost 2001; 85: 430-434

11. Thomson NP, Wakefield AJ, Founder RE: Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology 1995; 108: 1011-1015

12. Chiarantini E, Valanzano R, Liotta AA, Cellai AP, Fedi S, Ilari I, Prisco D, Tonelli F, Abbate R: Hemostatic abnormalities in inflammatory bowel disease. Thromb Res 1996; 82: 137-146

13. Wakefield AJ, Sawyerr AM, Dhillon AP, Pittilo RM, Rowles PM, Lewis AA, Founder RE: Pathogenesis of Crohn’s disease: Multifocal gastrointestinal infarction. Lancet 1989; 2: 1057-1062

14. Papa A, Danese S, Grillo A, Gasbarrini G, Gasbarrini A: Review article: Inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1247-1251

15. Tsoulakidou G, Koutroubakis IE: Thrombosis and inflammatory bowel disease-the role of genetic risk factors. World J Gastroenterol 2008; 14 (28): 4440-4444

16. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67

17. Selingsohn U, Lubetsky A: Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-1231

18. Rees DC, Cox M, Clegg JB: Word distribution of factor V Leiden. Lancet 1995; 346: 1133-1134

19. Liebman HA, Kashani N, Sutherland D, McGehee W, Kam AL: The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease. Gastroenterology 1998; 11: 830-834

20. Over HH, Ulgen S, Tuglular T, Tezel A, Aysar E, Geyik G, Bagel S, Sayhan N, Ulusoy N, Kalayci C, Tözün N: Thrombophilia and inflammatory bowel disease: Does factor V mutation have a role? Eur J Gastroenterol Hepatol 1998; 10: 827-829

21. Akar N: Factor V 1691 G-A mutation distribution in a healthy Turkish population. Turk J Hematol 2009; 26: 9-11

22. Haslam N, Standen GR, Probert CS: An investigation of the association of the factor V Leiden mutation and inflammatory bowel disease. Eur J Gastroenterol Hepatol 1999; 11: 1289-1291

23. Cakal B, Gokmen A, Yalinkilic M, Cakal E, Ayaz S, Nadir I, Ozin Y, Dagli U, Ulker A: Natural anticoagulant protein levels in Turkish patients with inflammatory bowel disease. Blood Coagulation and Fibrinolysis 2010; 21: 118-121

24. Novacek G, Miehsler W, Kapistis S, Katzenschlager R, Speiser W, Vogelsang H: Thrombembolism and resistance to activated protein C in patients with inflammatory bowel disease. Gastroenterology 1999; 94: 685-690

25. Halsam N, Standen GR, Probert CS: An investigation of the association of the prothrombin G202210A gene mutation and inflammatory bowel disease. Eur J Gastroenterol Hepatol 1998; 10: 827-829

26. Welch GN, Loscalzo J: Homocysteine and Atherothrombosis. N Engl J Med 1998; 338: 1042-1050

27. Saibeni S, Cattaneo M, Vecchi M, Zighetti ML, Lecchi A, Tamellini L, Baxter C, Dias AM, Gentili A, Grange P, Mietto M, Gatti A, Piazzoni L, Papi C, Zaghi S, Casaccia L, Frittoli G, Sesti A, Pollicino C, Corelli F, Semb D, Anselmo C, Bonadonna RC, Barcellona P, Scharfetter-Kochanek K, Capuzzi M, Egidi M, Rovati LC: Molecular epidemiology of factor V Leiden in a population at high risk for venous thromboembolism. Thromb Haemost 2001; 85: 132-138

28. Papa A, De Stefano V, Danese S, Chiusolo P, Persichilli S, Casorelli I, Zappacosta B, Giardina B, Gasbarrini A, Leone G, Gasbarrini G: Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease. Am J Gastroenterol 2001; 96: 2677-2682
29. Oldenburg B, Fijnheer R, van der Griend R, van Berge-Henegouwen GP, Koningsberger JC: Homocysteine in inflammatory bowel disease: A risk factor for thromboembolic complications? Am J Gastroenterol 2000; 95: 2825-2830
30. Romagnuolo J, Fedorak RN, Dias VC, Bamforth F, Telscher M: Hyperhomocysteinemia and inflammatory bowel disease: Prevalence and predictors in a cross-sectional study. Am J Gastroenterol 2001; 96: 2143-2149
31. Mahmud N, Molloy A, McPartlin J, Corbally R, Whitehead AS, Scott JM, Weir DG: Increased prevalence of methyltetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications. Gut 1999; 45: 389-394
32. Vecchi M, Sacchi E, Saibeni S, Meucci G, Tagliabue L, Duca F, De Franchis R: Inflammatory bowel diseases are not associated with major hereditary conditions predisposing to thrombosis. Dig Dis Sci 2000; 45: 1465-1469
33. Guédon C, Le Cam-Duchez V, Lalaude O, Ménard JF, Lerebours E, Borg JY: Prothrombotic inherited abnormalities other than factor V Leiden mutation do not play a role in venous thrombosis in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 1448-1454
34. Botto LD, Yang Q: 5,10- Methyltetrahydrofolate reductase gene variants and congenital abnormalities: A HuGe review. Am J Epidemiol 2000; 151: 862-877
35. Gusella JF, Podolsky DK: Inflammatory bowel disease: Is it specific of celiac disease? J Clin Invest 1995; 95: 3457-3461
36. van Dullemen H, Meenan J, Stronkhorst A, Tytgat GN, van Deventer SJ: Mediators of mucosal inflammation: Implications for therapy. Scand J Gastroenterol Suppl 1997; 223: 92-98
37. Wardle TD, Hall L, Turnberg LA: Platelet activating factor: Release from colonic mucosa in patients with ulcerative colitis and its effect on colonic secretion. Gut 1996; 38: 355-361
38. Esmon CT: Inflammation and thrombosis. J Thromb Haemost 2003; 1: 1343-1348
39. Kapsoiritakis AN, Potamianos SP, Sfridaki Al, Koukourakis MI, Koutoubakis IE, Roussomoustakaki MI, Manousos ON, Kouroumalis EA: Elevated thrombopoietin levels in patients with inflammatory bowel disease. Am J Gastroenterol 2000; 95: 3478-3481
40. Pamuk GE, Vural O, Turgut B, Demir M, Umit H, Tezel A: Increased circulating platelet-neutrophil, platelet-monocyte complexes and platelet activation in patients with ulcerative colitis: A Comparative Study. Am J Hematol 2006; 81: 753-759
41. Kjeldsen J, Lassen JF, Brandslund I, Schaffalitzky de Muckadell OB: Markers of coagulation and fibrinolysis as measures of disease activity in inflammatory bowel disease. Scand J Gastroenterol 1998; 33: 637-643
42. Saibeni S, Saladino V, Chantarangkul V, Villa F, Bruno S, Vecchi M, Franchis R, Sei C, Tripodi A: Increased thrombin generation in inflammatory bowel diseases. Thromb Res 2010; 125: 278-282
43. Danese S, Papa A: PAI-1 and TAFI in inflammatory bowel disease: The Yin and Yang of the fibrinolytic system. Eur J Gastroenterol Hepatol 2008; 20: 826-828
44. Grainge MJ, West J, Card TR: Venous thromboembolism during active disease and remission in inflammatory bowel disease: A cohort study. Lancet 2010; 375: 657-663
45. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N: A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341 (11): 793-800
46. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowsk W, Turpie AG, Egberts JF, Lensing AW; ARTEMIS Investigators: Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: Randomised placebo controlled trial. BMJ 2006; 332: 325-329
47. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ: Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-879
48. Cohen AT, Alikhan R, Arcelus JJ, Bergmann JF, Haas S, Merli GJ, Spyropoulos AC, Tapson VF, Turpie AG: Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 2005; 94 (4): 750-759
49. Papa A, Danese S, Gasbarrini A, Gasbarrini G: Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 1403-1409
50. Day R, Forbes A: Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease. Lancet 1999; 354: 62-65
51. Young E: The anti-inflammatory effects of heparin and related compounds. Thrombosis Research 2008; 122: 743-752
52. Gaffney PR, Doyle CT, Gaffney A, Hogan J, Hayes DP, Annis P: Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 1995; 90: 220-223
53. Evans RC, Wong VS, Morris AI, Rhodes JM: Treatment of corticosteroid resistant ulcerative colitis with heparin-a report of 16 cases. Aliment Pharmacol Ther 1997; 11: 1037-1040
54. Folwaczny C, Wiebecke B, Loeschke K: Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am J Gastroenterol 1999; 94: 1551-1555

55. Torkvist L, Thorlacius H, Sjöqvist U, Bohman L, Lapidus A, Flood L, Agren B, Raud J, Lofberg R: Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1323-1328

56. Bloom S, Kiilerich S, Lassen MR, Forbes A, Leiper K, Langholz E, Irvine EJ, O’Morain C, Lowson D, Orm S: Low molecular weight heparin (tinzaparin) vs placebo in the treatment of mild to moderate active ulcerative colitis. Aliment Pharmacol Ther 2004; 19: 871-878

57. Shen J, Ran ZH, Tong JL, Xiao SD: Meta-analysis: The utility and safety of heparin in the treatment of active ulcerative colitis. Aliment Pharmacol Ther 2007; 653-663

58. Travis SP, Stange EF, Lémann M, Oresland T, Bemelman WA, Chowers Y, Colombel JF, D’Haens G, Ghosh S, Marteau P, Kruis W, Mortensen NJ, Penninckx F, Gassull M; for the European Crohn’s and Colitis Organisation (ECCO): European evidence-based consensus on the management of ulcerative colitis: Current management. J Corhn’s & Colitis 2008; 2: 24-62